Insider · CIK 0001329154

Rosenblum Mark J

Reports to the SEC for 4 companies · HOUSTON, TX

sec.gov

Transactions

Companies

Filings

CIK

0001329154

Forms 4 and 5

Insider transactions

39 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-31	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+9,682 sh	—	—	11,363
2025-11-20	DCOYDecoy Therapeutics Inc.P Purchase	Chief Financial Officer	PPurchase	+20K sh	$0.80	+$16K	20,177
2024-02-20	DCOYDecoy Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+22.5K sh	—	—	22,500
2023-02-13	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+6,432 sh	—	—	21,851
2023-01-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+8,000 sh	—	—	15,419
2022-11-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+7,314 sh	$1.73	+$12.7K	13,245
2022-11-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+1,488 sh	$1.73	+$2,580.192	7,419
2022-11-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+7,314 sh	$1.73	+$12.7K	155,633
2022-05-31	DCOYDecoy Therapeutics Inc.P Purchase	Chief Financial Officer	PPurchase	+28K sh	$0.18	+$5,040	148,319
2022-05-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+10K sh	$0.19	+$1,863	120,319
2022-03-03	DCOYDecoy Therapeutics Inc.P Purchase	Chief Financial Officer	PPurchase	+76.2K sh	$0.39	+$29.8K	110,319
2022-01-20	DCOYDecoy Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+200K sh	—	—	200,000
2021-11-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+7,787 sh	$0.72	+$5,591.066	34,073
2021-05-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+9,563 sh	$0.57	+$5,422.221	26,286
2020-12-02	DCOYDecoy Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+80K sh	—	—	80,000
2020-11-03	DCOYDecoy Therapeutics Inc.A Award	Chief Financial Officer	AAward	+4,723 sh	$0.56	+$2,649.603	16,723
2020-08-17	DCOYDecoy Therapeutics Inc.P Purchase	Chief Financial Officer	PPurchase	+5,000 sh	$1.00	+$5,000	12,000
2020-07-14	DCOYDecoy Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+50K sh	—	—	49,955
2020-03-23	DCOYDecoy Therapeutics Inc. · Common StockA Award	Chief Financial Officer	AAward	+30K sh	—	—	30,000
2020-02-19	DCOYDecoy Therapeutics Inc.P Purchase	Chief Financial Officer	PPurchase	+2,000 sh	$0.95	+$1,900	7,000
2020-02-13	DCOYDecoy Therapeutics Inc.P Purchase	Chief Financial Officer	PPurchase	+5,000 sh	$0.86	+$4,295	5,000
2014-01-31	Ayala Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+530 sh	—	—	113,822
2014-01-31	Ayala Pharmaceuticals, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−48 sh	$4.49	−$215.52	113,774
2014-01-07	Ayala Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+20K sh	—	—	41,616
2014-01-07	Ayala Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+80K sh	—	—	121,616
2014-01-07	Ayala Pharmaceuticals, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−8,324 sh	$4.03	−$33.5K	113,292
2014-01-07	Ayala Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+2,985 sh	—	—	23,181
2014-01-07	Ayala Pharmaceuticals, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−1,565 sh	$4.03	−$6,306.95	21,616
2013-10-24	Ayala Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+12K sh	$4.00	+$48K	20,196
2013-10-24	Ayala Pharmaceuticals, Inc.Common Stock WarrantsP Purchase	Chief Financial Officer	PPurchase	+6,000 sh	$0.00	+$6	6,000
2013-03-14	Ayala Pharmaceuticals, Inc.OptionA Award	Chief Financial Officer	AAward	+2.4M sh	—	—	2,400,000
2012-05-14	Ayala Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+686K sh	—	—	686,275
2012-05-14	Ayala Pharmaceuticals, Inc.Convertible Promissory NoteD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	—	—	—	—
2012-05-14	Ayala Pharmaceuticals, Inc.Common Stock Warrants (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−196K sh	—	—	0
2011-11-08	Ayala Pharmaceuticals, Inc.OptionsA Award	Chief Financial Officer	AAward	+2.1M sh	—	—	2,100,000
2011-10-31	Ayala Pharmaceuticals, Inc.Convertible Promissory NoteA Award	Chief Financial Officer	AAward	—	—	—	—
2011-10-31	Ayala Pharmaceuticals, Inc.Common Stock Warrants (right to buy)A Award	Chief Financial Officer	AAward	+196K sh	—	—	196,078
2010-10-14	Ayala Pharmaceuticals, Inc.OptionsA Award	Chief Financial Officer	AAward	+1.2M sh	—	—	1,200,000
2009-03-04	HEMOBIOTECH, INC.A Award	Chief Financial Officer	AAward	+65K sh	—	—	293,234

Recent filings

Accepted (ET)
Sep 24
Rosenblum Mark J0001329154-26-000003
SEC(opens sec.gov)
Nov 204
Rosenblum Mark J0001615219-25-000177
SEC(opens sec.gov)
Feb 224
Rosenblum Mark J0001615219-24-000015
SEC(opens sec.gov)
Feb 154
Rosenblum Mark J0001615219-23-000025
SEC(opens sec.gov)
Jan 54
Rosenblum Mark J0001615219-23-000004
SEC(opens sec.gov)
Dec 124/A
Rosenblum Mark J0001615219-22-000153
SEC(opens sec.gov)
Nov 84/A
Rosenblum Mark J0001615219-22-000143
SEC(opens sec.gov)
Nov 74
Rosenblum Mark J0001615219-22-000141
SEC(opens sec.gov)
May 314
Rosenblum Mark J0001615219-22-000085
SEC(opens sec.gov)
May 54
Rosenblum Mark J0001615219-22-000067
SEC(opens sec.gov)
Mar 94
Rosenblum Mark J0001615219-22-000019
SEC(opens sec.gov)
Jan 214
Rosenblum Mark J0001615219-22-000004
SEC(opens sec.gov)
Nov 54
Rosenblum Mark J0001615219-21-000095
SEC(opens sec.gov)
May 54
Rosenblum Mark J0001615219-21-000042
SEC(opens sec.gov)
Dec 44
Rosenblum Mark J0001615219-20-000120
SEC(opens sec.gov)
Nov 54
Rosenblum Mark J0001615219-20-000104
SEC(opens sec.gov)
Aug 184
Rosenblum Mark J0001615219-20-000092
SEC(opens sec.gov)
Jul 164
Rosenblum Mark J0001615219-20-000080
SEC(opens sec.gov)
Mar 254
Rosenblum Mark J0001615219-20-000027
SEC(opens sec.gov)
Feb 204
Rosenblum Mark J0001615219-20-000005
SEC(opens sec.gov)

Companies

Address

2450 HOLCOMBE BLVD STE X

HOUSTON, TX, 77021